Dominic Enders
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dominic Enders has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Antje Westendorf
Institute of Medical Informatics, University of Münster
2 shared publications - Frieder Schaumburg
Institute of Medical Microbiology, University of Münster, Germany
2 shared publications - Niklas Wiesmann
University Hospital Münster Institute of Medical Microbiology Münster, 48149
2 shared publications - Raphael Koch
Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany
2 shared publications - Astrid Elisabeth Lammers
Department of Cardiology III - Adult Congenital and Valvular Heart Disease, University Hospital Muenster, Muenster, Germany
1 shared publication Fernando De-Torres-Alba
Department of Cardiology III, Adult Congenital and Valvular Heart Disease, University Hospital Muenster , Albert-Schweitzer-Campus 1 , 48149 Münster, Germany
1 shared publication
Latest Publications
- Open Access
- 11 March 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (3) , e0188425
Correction for Wiesmann et al., “Prediction of antimicrobial resistance from MALDI-TOF mass spectra using machine learning: a validation study”
- 11 March 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (3) , e0188425
Open AccessCorrection for Wiesmann et al., “Prediction of antimicrobial resistance from MALDI-TOF mass spectra using machine learning: a validation study”
- Top Cited PapersOpen Access
- 17 December 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (12) , e0118625
Prediction of antimicrobial resistance from MALDI-TOF mass spectra using machine learning: a validation study
Matrix-assisted laser desorption-ionization-time of flight (MALDI-TOF) mass spectra can be used to predict antimicrobial resistance (AMR) using machine learning (ML). This study aimed to validate the performance of ML models for AMR prediction using own and publicly available MALDI-TOF data and to test how these models perform over time. Mass spectra of Escherichia coli ( n = 7,897), Klebsiella pneumoniae ( n = 2,444), and Staphylococcus aureus ( n = 4,664) from routine diagnostics (Germany) and the DRIAMS-A database (Switzerland) were used. Six classification models were benchmarked for AMR prediction using cross-validation (regularized logistic regressions [LR], multilayer perceptrons [MLP], support vector machines [SVM], random forests [RF], gradient boosting machines [LGBM, XGB]). Performance was prospectively observed for 18 months after training. The performance of AMR prediction evaluated by the mean area under the receiver operating characteristic curve (AUROC) was comparable between the DRIAMS-A data set and own data. The best predictive performance (classifier, AUROC) on own data was achieved for oxacillin resistance in S. aureus (RF, 0.85), ciprofloxacin resistance in E. coli (XGB, 0.83), and piperacillin-tazobactam resistance in K. pneumoniae (XGB, 0.81). ML performance was poor if training and test data were unrelated in terms of location and time. Performance (change in AUROC) decreased within 18 months after training for S. aureus (oxacillin resistance, RF: −0.10), E. coli (ciprofloxacin, XGB: −0.19), and K. pneumoniae (piperacillin-tazobactam, XGB: −0.25). The performance of ML for the prediction of AMR based on MALDI-TOF data is good (AUROC ≥ 0.8) but classifiers need to be trained on local data and retrained regularly to maintain the performance level. IMPORTANCE: MALDI-TOF mass spectrometry can be used not only for bacterial species identification but also for the prediction of antimicrobial resistance (AMR) using machine learning (ML). Such an approach would provide antimicrobial susceptibility test results one day earlier than conventional routine diagnostics. This is essential for an early targeted treatment to reduce mortality of severe infections. We show that the performance of ML for the prediction of AMR based on MALDI-TOF data is good (AUROC ≥ 0.8). However, the ML models need to be trained on local data and retrained regularly to maintain a good performance.
- 17 December 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (12) , e0118625
Top Cited PapersOpen AccessPrediction of antimicrobial resistance from MALDI-TOF mass spectra using machine learning: a validation study
Matrix-assisted laser desorption-ionization-time of flight (MALDI-TOF) mass spectra can be used to predict antimicrobial resistance (AMR) using machine learning (ML). This study aimed to validate the performance of ML models for AMR prediction using own and publicly available MALDI-TOF data and to test how these models perform over time. Mass spectra of Escherichia coli ( n = 7,897), Klebsiella pneumoniae ( n = 2,444), and Staphylococcus aureus ( n = 4,664) from routine diagnostics (Germany) and the DRIAMS-A database (Switzerland) were used. Six classification models were benchmarked for AMR prediction using cross-validation (regularized logistic regressions [LR], multilayer perceptrons [MLP], support vector machines [SVM], random forests [RF], gradient boosting machines [LGBM, XGB]). Performance was prospectively observed for 18 months after training. The performance of AMR prediction evaluated by the mean area under the receiver operating characteristic curve (AUROC) was comparable between the DRIAMS-A data set and own data. The best predictive performance (classifier, AUROC) on own data was achieved for oxacillin resistance in S. aureus (RF, 0.85), ciprofloxacin resistance in E. coli (XGB, 0.83), and piperacillin-tazobactam resistance in K. pneumoniae (XGB, 0.81). ML performance was poor if training and test data were unrelated in terms of location and time. Performance (change in AUROC) decreased within 18 months after training for S. aureus (oxacillin resistance, RF: −0.10), E. coli (ciprofloxacin, XGB: −0.19), and K. pneumoniae (piperacillin-tazobactam, XGB: −0.25). The performance of ML for the prediction of AMR based on MALDI-TOF data is good (AUROC ≥ 0.8) but classifiers need to be trained on local data and retrained regularly to maintain the performance level. IMPORTANCE: MALDI-TOF mass spectrometry can be used not only for bacterial species identification but also for the prediction of antimicrobial resistance (AMR) using machine learning (ML). Such an approach would provide antimicrobial susceptibility test results one day earlier than conventional routine diagnostics. This is essential for an early targeted treatment to reduce mortality of severe infections. We show that the performance of ML for the prediction of AMR based on MALDI-TOF data is good (AUROC ≥ 0.8). However, the ML models need to be trained on local data and retrained regularly to maintain a good performance.
- Open Access
- 12 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (41) , 4252-4260
Maternal and neonatal complications in women with congenital heart disease: a nationwide analysis
The aim of this study was to provide population-based data on maternal and neonatal complications and outcome in the pregnancies of women with congenital heart disease (CHD). Based on administrative data from one of the largest German Health Insurance Companies (BARMER GEK, ∼9 million members representative for Germany), all pregnancies in women with CHD between 2005 and 2018 were analysed. In addition, an age-matched non-CHD control group was included for comparison and the association between adult CHD (ACHD) and maternal or neonatal outcomes investigated. Overall, 7512 pregnancies occurred in 4015 women with CHD. The matched non-CHD control group included 6502 women with 11 225 pregnancies. Caesarean deliveries were more common in CHD patients (40.5% vs. 31.5% in the control group; P < 0.001). There was no excess mortality. Although the maternal complication rate was low in absolute terms, women with CHD had a significantly higher rate of stroke, heart failure and cardiac arrhythmias during pregnancy (P < 0.001 for all). Neonatal mortality was low but also significantly higher in the ACHD group (0.83% vs. 0.22%; P = 0.001) and neonates to CHD mothers had low/extremely low birth weight or extreme immaturity (<0.001) or required resuscitation and mechanical ventilation more often compared to non-CHD offspring (P < 0.001 for both). On multivariate logistic regression maternal defect complexity, arterial hypertension, heart failure, prior fertility treatment, and anticoagulation with vitamin K antagonists emerged as significant predictors of adverse neonatal outcome (P < 0.05 for all). Recurrence of CHD was 6.1 times higher in infants to ACHD mothers compared to controls (P < 0.0001). This population-based study illustrates a reassuringly low maternal mortality rate in a highly developed healthcare system. Nevertheless, maternal morbidity and neonatal morbidity/mortality were significantly increased in women with ACHD and their offspring compared to non-ACHD controls highlighting the need of specialized care and pre-pregnancy counselling. Overview over the main findings of the study. The results illustrate significantly increased risk of maternal and neonatal complications as well as a significantly increased risk of recurrence of congenital heart disease in the children of congenital heart disease mothers. For details, please see Tables 1–4.
- 12 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (41) , 4252-4260
Open AccessMaternal and neonatal complications in women with congenital heart disease: a nationwide analysis
The aim of this study was to provide population-based data on maternal and neonatal complications and outcome in the pregnancies of women with congenital heart disease (CHD). Based on administrative data from one of the largest German Health Insurance Companies (BARMER GEK, ∼9 million members representative for Germany), all pregnancies in women with CHD between 2005 and 2018 were analysed. In addition, an age-matched non-CHD control group was included for comparison and the association between adult CHD (ACHD) and maternal or neonatal outcomes investigated. Overall, 7512 pregnancies occurred in 4015 women with CHD. The matched non-CHD control group included 6502 women with 11 225 pregnancies. Caesarean deliveries were more common in CHD patients (40.5% vs. 31.5% in the control group; P < 0.001). There was no excess mortality. Although the maternal complication rate was low in absolute terms, women with CHD had a significantly higher rate of stroke, heart failure and cardiac arrhythmias during pregnancy (P < 0.001 for all). Neonatal mortality was low but also significantly higher in the ACHD group (0.83% vs. 0.22%; P = 0.001) and neonates to CHD mothers had low/extremely low birth weight or extreme immaturity (<0.001) or required resuscitation and mechanical ventilation more often compared to non-CHD offspring (P < 0.001 for both). On multivariate logistic regression maternal defect complexity, arterial hypertension, heart failure, prior fertility treatment, and anticoagulation with vitamin K antagonists emerged as significant predictors of adverse neonatal outcome (P < 0.05 for all). Recurrence of CHD was 6.1 times higher in infants to ACHD mothers compared to controls (P < 0.0001). This population-based study illustrates a reassuringly low maternal mortality rate in a highly developed healthcare system. Nevertheless, maternal morbidity and neonatal morbidity/mortality were significantly increased in women with ACHD and their offspring compared to non-ACHD controls highlighting the need of specialized care and pre-pregnancy counselling. Overview over the main findings of the study. The results illustrate significantly increased risk of maternal and neonatal complications as well as a significantly increased risk of recurrence of congenital heart disease in the children of congenital heart disease mothers. For details, please see Tables 1–4.